Regulatory Exclusivity Rights and Medicines
This chapter provides a detailed analysis of the rules that govern the award of regulatory exclusivity rights, which focuses on the EU law. It talks about the arrangements around Northern Ireland that will incentivize the UK and EU to stay in close alignment in heavily regulated product markets, such as pharmaceuticals. It also sets out an overview of the law surrounding the full and abridged generic marketing authorization applications from an exclusivity perspective. The chapter covers some of the seminal judicial decisions, which demonstrate the legal challenges and decisions that have shaped the current position. It provides a summary of the basics of data and market exclusivity in the EU.